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Tuberculosis (TB) is the most common opportunistic infection in human immunodeficiency virus (HIV)-infected patients and
the emergence of drug-resistant tuberculosis (DR-TB) is a growing problem in resource-limited settings. Adequate infrastruc-
ture for testing drug sensitivity and sufficient evidence of first-line resistance are currently unavailable in Nigeria. We collected
sputum samples fromHIV-infected patients enrolled in the Harvard PEPFAR/APIN Plus program over 12 months at two
PEPFAR antiretroviral therapy (ART) clinics in the southwest and north central regions in Nigeria. Smear-positive sputum sam-
ples were submitted for GenoTypeMTBDRplus testing (n 415); mutations were confirmed through sequencing. Our results
show high rates of DR-TB in Nigerian HIV-infected individuals (7.0% for rifampin [RIF] and 9.3% for RIF or isoniazid [INH]).
Total RIF resistance indicative of MDR-TB in treatment-naive patients was 5.52%, far exceeding theWorld Health Organization
predictions (0 to 4.3%). RIF resistance was found in 6/213 (2.8%) cases, INH resistance was found in 3/215 (1.4%) cases, and
MDR-TB was found in 8/223 (3.6%) cases. We found significantly different amounts of DR-TB by location (18.18% in the south
of the country versus 3.91% in the north central region [P< 0.01]). Furthermore, RIF resistance was genetically distinct, sug-
gesting possible location-specific strains are responsible for the transmission of drug resistance (P< 0.04). Finally, GenoType
MTBDRplus correctly identified the drug-resistant samples compared to sequencing in 96.8% of cases. We found that total
DR-TB in HIV-infection is high and that transmission of drug-resistant TB in HIV-infected patients in Nigeria is higher than
predicted.
Human immunodeficiency virus (HIV) greatly increases therisk for tuberculosis (TB), and the two epidemics continue to
fuel one another (31). HIV-infected patients are significantly
more likely to develop active TB diseases than non-HIV-infected
people and are more likely to die from TB (13, 27, 28). In sub-
Saharan Africa, 30% of HIV-infected patients who are diagnosed
with TB die 12 months after the initiation of treatment (12, 33).
With an estimated national prevalence of HIV in Nigeria of 3.6%
(7), the number of people living withHIV (3.3million) represents
the second largest burden of disease on the continent (32). Nigeria
has the world’s third largest TB burden, with the prevalence of
830,000 cases. The World Health Organization (WHO) estimates
that 26% of patients with TB infection in Nigeria are HIV infected
(37).
Multidrug-resistant TB (MDR-TB), defined by resistance to
isoniazid (INH) and rifampin (RIF), is a growing global health
problem (5, 19, 22). While MDR-TB emerges as a consequence of
poor adherence to anti-TB treatment (34, 35), it can also be trans-
mitted. MDR-TB results in significantly higher mortality rates in
HIV-infected patients than drug-susceptible TB (18). The esti-
mates based on modeling predict MDR-TB prevalence in Nigeria
to range from 1.8% (0.0 to 4.3%) for new cases up to 7.7% (0.0 to
18.0%) for previously treated patients (36). Currently in Nigeria,
streptomycin is the only treatment available for patients previ-
ously treated for TB or suspected of infection withMDR-TB. Fur-
thermore, MDR-TB in HIV-infected individuals leads to higher
mortality compared to mortality in non-HIV-infected patients or
HIV-infected individuals with susceptible TB (18, 24). These find-
ings, combined with alarming evidence that MDR-TB can be
transmitted, calls for close monitoring of the incidence of drug
resistance, especially in HIV-infected populations (6).
The conventional methods of drug resistance testing involve
growth of Mycobacterium tuberculosis on liquid or solid culture
medium (35). Culture methods are costly and time-consuming,
thus limiting both utility for patient care and likelihood of timely
treatment. Recently, several new commercial tests have been de-
scribed that identify MDR-TB based on the genetic sequence; one
is a line probe assay named GenoType MTBDRplus, which diag-
noses TB and identifies drug resistance. It specifically examines
samples for classic geneticmutations that confer resistance to both
INH and RIF. Due to the reported efficiency and low cost of this
test, it represents an alternative to conventional drug sensitivity
testing through culture. The test has been successfully used in
several locations worldwide with high sensitivity rates for RIF
(95.5%) and INH (81.8%) resistance (2, 4, 15, 17, 21, 23) and
100% specificity (2, 4, 15, 17, 21, 23).
TheGenoTypeMTBDRplus test is also reliable as amethod for
surveillance of drug resistance (26). The surveillance and moni-
toring of both INH- and RIF-resistant M. tuberculosis is not only
beneficial for an individual patient but also for the HIV-infected
population as a whole, since they are more susceptible to M.
tuberculosis infection (10). Implementation of the GenoType
Received 23 April 2012 Returned for modification 28 May 2012
Accepted 14 June 2012
Published ahead of print 27 June 2012
Address correspondence to Phyllis Kanki, pkanki@hsph.harvard.edu.
Supplemental material for this article may be found at http://jcm.asm.org/.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.00982-12
September 2012 Volume 50 Number 9 Journal of Clinical Microbiology p. 2905–2909 jcm.asm.org 2905
MTBDRplus test as a routine test can have a significant impact by
improving the lives of HIV-infected patients with TB. It is there-
fore imperative to identify the individuals at highest risk of acquir-
ing the drug-resistantM. tuberculosis strains in Nigeria in order to
develop a programmatic policy to prevent further transmission.
MATERIALS AND METHODS
Two geographically distinct locations in Nigeria were chosen, the Nige-
rian Institute for Medical Research (NIMR) in Lagos and the Jos Univer-
sity TeachingHospital (JUTH), located in the southwest andnorth central
zones of the country, respectively. NIMR data were collected from June
2009 to June 2010, and JUTH data were collected between August 2009
and November 2010. The ethical approval was obtained from the institu-
tional review boards at NIMR, JUTH, and Harvard School of Public
Health (approval 16430-103).
At regular clinic visits, HIV-infected patients were screened for symp-
toms of pulmonary TB, including chest pain, cough lasting more than 2
weeks, fever, night sweats, and weight loss. Upon identification, patients
were asked to participate in the study and provided written informed
consent. Consented patients were queried about their TB history to assess
their treatment exposure prior to the study and asked to provide three
sputum samples. All samples were decontaminated using the modified
Petroff method and stained directly for acid-fast bacilli (AFB) using the
Ziehl-Neelsen method (20). Patients with AFB-positive samples were en-
rolled in the study for a 12-month period.
Samples identified as sputum smear positive (SS) for AFB were in-
cluded in the study. Crude DNA extraction was performed on site, fol-
lowed by PCR andhybridization on test strips, according to theGenoType
MTBDRplus (Hain Lifesciences, Nehren, Germany) protocol (11). Iso-
lated DNA was stored at20°C until the genotypic resistance testing was
performed. GenoTypeMTBDRplus test instructions were followed forM.
tuberculosis DNA amplification and hybridization (11). The tests strips
were scored for resistance based on the presence of a mutant strain or the
absence of wild-type DNA.
Multiplex-nested PCR and DNA sequencing of resistance genes.
Samples diagnosed as resistant with the GenoType MTBDRplus test and
16 susceptible samples from the same cohort were sequenced. Portions (5
to 10 l) of crude lysate were used to amplify the four resistance-confer-
ring genes (rpoB, katG, the inhA promoter, and the oxyR-ahpC intergenic
regulatory region) using a multiplex PCR. The PCR was established using
1 KOD polymerase buffer, 0.2 mM deoxynucleoside triphosphate
(each), 1.5mMMgSO4, 5%dimethyl sulfoxide, 100 nMconcentrations of
each primer, and 1%KODHot Start polymerase (Toyobo, Osaka, Japan).
Cycling consisted of 1 cycle of 3 min at 95°C, followed by 25 cycles of 20 s
at 95°C, 10 s at 63°C, and 15 s at 72°C, and then 1 cycle of 2 min at 72°C.
A nested PCRwas performed individually on each gene using 5 to 10l of
the multiplex sample. The reagent concentrations were identical to the
multiplex PCR, except that 200 nM inner primer was used. The nested
PCR protocol consisted of 1 cycle of 3 min at 95°C, followed by 30 cycles
of 20 s at 95°C and 10 to 15 s of annealing/extension at various tempera-
tures (rpoB and inhA,10 s for 60°C and 5 s for 72°C; katG, 10 s for 65°C;
oxyR-ahpC, 10 s for 62°C and 5 s for 72°C).
The nested PCR products were then separated through electrophore-
sis on a 2%NuSieve (Lonza, Rockland, ME) agarose gel. The bands of the
appropriate sizes were excised and purified from the gel using aMinElute
kit (Qiagen, Hilden, Germany) according to themanufacturer’s protocol.
After the PCR fragment concentrations were evaluated using a Quant-iT
PicoGreen (Invitrogen, Carlsbad, CA), 10 ng of the DNA was used for
sequencing with a BigDye Terminator (v1.1; Applied Biosystems, Carls-
bad, CA) cycle sequencing kit on an Applied Biosystems 3100 sequencing
instrument. Primers used for sequencing were the inner primers of the
multiplex-nested PCR, except for the inhA promoter region that used
separate primers (see Table S1 in the supplemental material).
Data analysis. Experimentally obtained sequences were aligned with
the known genetic sequence of a susceptibleM. tuberculosis strain H37Rv
using Lasergene (DNAStar, Madison, WI) and examined for previously
reported resistance associatedmutations. The sequence consensus of each
sample was compared to the GenoType MTBDRplus results to assess the
two genotypic evaluations of resistance. Groups of resistant samples were
compared using the Fisher exact test, while patient characteristics at study
entry were compared using the chi-square or Wilcoxon rank-sum test as
appropriate. Significance threshold was set to P 0.05.
RESULTS
A total of 940 patients presented with signs and symptoms of TB,
while 535 had at least one AFB sputum. Of 415 available patient
samples that were tested with GenoType MTBDRplus, genes rep-
resentative of RIF susceptibility could be evaluated for 213 cases,
INH susceptibility for 215 cases, and MDR-TB for 223 cases. RIF
resistancewith theGenoTypeMTBDRplus testwas evaluatedwith
the hybridized band profile of the rpoB gene, while INH was eval-
uated by hybridization to the katG open reading frame and the
inhA promoter sequence. When we compared patients by site,
there were no statistically significant differences in age (median,
36 years; P  0.72), evidence of previous TB treatment (JUTH,
n  37; NIMR, n  17 [P  0.17]), or the percentages of female
patients with 53.7% at JUTH and 64.4% at NIMR (P  0.11).
There were differences in time from symptom onset to clinic pre-
sentation (4 weeks at JUTH versus 3 weeks at NIMR; P  0.01)
(Table 1).
A greater number of resistant samples were observed at NIMR
(n  14) than at JUTH (n  5) (P  0.001). The percentage of
resistant samples for each drug, but not for both (MDR-TB), dem-
onstrated significantly higher rates of resistance at NIMR com-
TABLE 1 Patient characteristics at study entry by site locationa
Characteristic
Patients (n 224)
PNIMR (n 90) JUTH (n 134)
Previous TB treatment 17 37 0.13
Median age in yrs (IQR) 35.62 (29.4–43.3) 35.99 (30.8–42.6) 0.72
Gender
Female 58 72 0.11
Male 32 62
Median no. of wks (IQR) between symptom onset and clinic presentation,
no. of observationsb
3 (2–3), 86 4 (3–8), 123 0.01
a NIMR, Lagos state, South-west region; JUTH, Plateau state, North-central region. Data refer to numbers of patients except as noted in column 1. IQR, interquartile range.
b Data available for a subset of patients.
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pared to JUTH (Table 2). Fifty-four patients had previous expo-
sure to TB treatment, while 170 were treatment naive. The
stratification based on patient’s prior treatment status showed no
significant differences between the prevalence of drug resistance
in naive versus pretreated patients (Table 3).
All of the polymorphisms found with the GenoType MTBDR-
plus test, the codons they identify, and the numbers of samples
with each profile by location are listed in Table 4. The GenoType
MTBDRplus resistance profile for RIF differed by study site,
where rpoB mutations from JUTH samples were predominantly
found in codons 526 to 529 (wt7), while the NIMR samples
showedmutations in codons 530 to 533 (wt8) (LG7 excluded, P
0.04). Genotype resistance profiles also indicate that mutations
conferring INH resistance in Nigeria occur at a similar rate in the
inhA promoter and the katG S315T region, in contrast to previous
reports (3, 14, 16). Furthermore, all of the mutations found in
katG were the same point mutation, S315T1, and the inhA pro-
moter was mutated at the C15T position.
Using the multiplex/nested PCR technique, we amplified and
sequenced most of the resistant samples (exceptions included
LG12, LG13, and LG14), as well as 16 susceptible samples directly
from sputum, to examine exact mutations found in resistance
conferring genes. The GenoType MTBDRplus susceptible sam-
ples showed no polymorphisms previously reported to be associ-
atedwith resistance (Table 4). Interestingly, each of the three sam-
ples from JUTH with a mutation in codon 526 of the rpoB gene
had a different point substitution responsible for resistance. The
most common mutation spanning the rpoBwt8 codon in NIMR
samples was S531L.
Only 2 of the 16 resistant samples (LG7 and LG4) and none of
16 susceptible samples had discordant results obtained from the
GenoTypeMTBDRplus test and sequencing. Sample LG7was still
resistant to RIF, and one of the three mutations indicated by
GenoType MTBDRplus was concordant (rpoBwt4 D516A). In-
stead of the mutations in the rpoBmut1 or rpoBwt8 region, a muta-
tion was observed in the rpoBwt2 region L511P.
In addition, although sample LG7 exhibited nomutations con-
ferring INH resistance in the katG or inhA promoter regions, it
was the only sample that had a C¡T substitution at location25
(in relation to the ahpC transcription start) of the oxyR-ahpC reg-
ulatory region, previously described only in inhA resistant strains
(14, 16, 25). Therefore, LG7 was not misdiagnosed for RIF resis-
tance, but potential inhA resistance could have beenmissed by not
including the oxyR-ahpC regulatory region in the assay.
Sample LG4 was designated as INH resistant by the GenoType
MTBDRplus test but was not confirmed by sequencing; instead,
the sample appeared to be susceptible according to its sequence
analysis. With LG4 identified as susceptible, INH resistance still
differed significantly by site (NIMR INH resistance 9.4% [P
0.03] versus JUTH; NIMR any resistance  16.9% [P  0.01]
versus JUTH). There was not a significant difference in any resis-
tance, including INH between treatment-naive and experienced
individuals.
In total, 1 of 31 sequenced samples (3.2%) did not confirm the
resistance diagnosis obtained with the GenoType MTBDRplus;
therefore, the concordance rate for DR-TB diagnosis was 96.8%
(oxyR-ahpC promoter region excluded). We sequenced a total
of 93 regions (rpoB, katG, and inhA) that are analyzed by the
GenoType MTBDRplus test. GenoType MTBDRplus misidenti-
fied only four mutations and was therefore 95.7% specific.
DISCUSSION
In Nigeria, HIV/TB coinfection rates are as high as 30% in anti-
retroviral therapy (ART) clinic settings, and the national preva-
lence of MDR-TB is unknown. Our results show high rates of
transmitted drug-resistant TB (5.5%), inferred by rates of rifam-
pin resistance in treatment-naive patients. This rate exceeds the
upper limit of the WHO MDR-TB models (4.3%). Furthermore,
AFB sputum smears, using the Ziehl-Neelsen stain, lack sensitivity
in identifying TB cases, and some cases ofM. tuberculosis infection
could have beenmissed. Since resistant bacteria are more likely to
be less fit than sensitive bacteria (1, 8, 9, 30) and therefore cause
paucibacillary disease, our resultsmay represent an underestimate
of drug resistance. This indicates that transmission of drug-resis-
tant TB is a more serious problem than previously anticipated.
TheGenoTypeMTBDRplus test correctly identifiedmutations
with a high concordance rate. In recent literature, the gene-based
identification of MDR-TB has gained prominence. The Gene-
Xpert MTB/RIF is considered an appropriate new technology for
diagnosing both TB and rifampin drug resistance. Although both
GeneXpert and GenoType MTBDRplus work on a similar princi-
ple—gene amplification and subsequent hybridization—Gene-
Xpert MTB/RIF does not examine INH resistance. Mutational
analysis of INH resistance is more complex than RIF because it
requires evaluating more genes. Furthermore, the genotypic anal-
ysis of rpoB for RIF resistance is thought to be sufficient for eval-
uating the public health threat of drug-resistant TB. However,
recent reports indicate that this remains controversial (29). In our
study, we observed 1.4% INH monoresistance and 2.8% RIF
monoresistance, highlighting the importance of evaluating both
drug susceptibilities. Although one case of INH resistance was
incorrectly identified with GenoType MTBDRplus, the inclusion
of inhA and katGmutation analysis in this test correctly identified
three INH-resistant, RIF-susceptible strains. This is particularly
important in HIV-prevalent settings where INH prophylaxis is
TABLE 2M. tuberculosis drug resistance in Nigerian HIV-infected
patients by location as determined by GenoType MTBDRplusa
Resistance type
No. of patients/total no. of patients
(%)
PNIMR JUTH
INH resistant 9/85 (10.59) 3/130 (2.31) 0.02
RIF resistant 11/81 (13.58) 4/132 (3.03) 0.01
MDR-TB 6/89 (6.74) 2/134 (1.49) 0.07
Any resistance 14/77 (18.18) 5/128 (3.91) 0.01
a NIMR, Lagos state southwest region; JUTH, Plateau state north central region.
TABLE 3M. tuberculosis drug resistance in Nigerian HIV-infected
patients by TB treatment history as determined by GenoType
MTBDRplus
Resistance type
No. of patients/total no. of patients (%)
PPreviously treated Treatment naive
INH resistant 4/50 (8.00) 8/165 (4.85) 0.48
RIF resistant 6/50 (12.00) 9/163 (5.52) 0.12
MDR-TB 3/54 (5.56) 5/169 (2.96) 0.40
Any resistance 7/46 (15.22) 12/159 (7.55) 0.15
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being considered. Such preventative measures might not be effec-
tive and could increase the rates of INH resistance, exacerbating
the diagnostic challenges for MDR-TB. Furthermore, misdiag-
nosing patients as MDR-TB when they are only RIF monoresis-
tant would lead to inappropriate second-line treatment, when
such treatment in resource-limited settings is already limited.
The baseline characteristics of age, gender, and prior treatment
status of patients did not show major site differences, indicating
that the sites were comparable. Although the duration of symp-
toms prior to clinic visit differed, this difference might be due to
the fact that patients visiting the clinic in Jos traveled longer dis-
tances and thereforewere at a disadvantage to be adherent to clinic
visits. In these two geographically distinct study populations, a
significantly higher number of drug-resistant TB was found in
Lagos compared to Jos. This phenomenon could be explained by
societal differences in the two cities, which might facilitate trans-
mission, Lagos beingmore densely populated with crowded living
arrangements and a congested public transportation system com-
pared to Jos. Transmission of drug-resistant TB in Lagos is further
suggested by the fact that 9 of 13 patients with drug-resistant TB
were treatment naive (versus 2/5 in Jos). An alternative explana-
tion is that the M. tuberculosis strains differed by location and
therefore so did their transmission and/or mutation rates. Al-
though we were not able to evaluate theM. tuberculosis strains or
their characteristics in the present study, themutations in the rpoB
gene are suggestive of such differences. All of the Jos mutations in
the rpoB gene were distinct, implying that they were acquired
through separate mutagenesis events, whereas most of the Lagos
strains had the same mutation (S531L) belonging to a potentially
more transmissible strain.
In summary, our study demonstrated high rates of drug-resis-
tant TB in HIV-infected patients. We also showed that the cost-
effective GenoType MTBDRplus test correctly identified resis-
tance-conferring mutations in the majority of samples examined
(95.7%). Although our sample size was small, this is the first mul-
tisite study of MDR-TB in HIV-infected population in Nigeria.
Consistent withWHO recommendations, our results support the
urgent need for systematic drug resistance testing in all HIV-in-
fected patients with symptoms suggestive of TB.
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